Atlanta, Georgia 30322

  • Hodgkin Lymphoma


Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

Study summary:

This is a Phase 1/2a, dose escalation, consecutive-cohort, open-label studytrial of BI-1206 in combination with rituximab in subjects with indolent relapsed or refractory B-cell NHL. The studytrial will consist of 2 main parts: Phase 1 (with dose escalation cohorts using a 3+3 dose-escalation design and selection of the RP2D), and Phase 2a (the escalationexpansion cohort at the RP2D). Subjects in each phase will receive 1 cycle (4 doses) of induction therapy with BI-1206 in combination with rituximab. Subjects who show clinical benefit (complete response [CR], partial response [PR], or stable disease [SD]) at Week 6 will continue onto maintenance therapy and receive BI-1206 and rituximab once every 8 weeks (relative to previous maintenance dose) for up to 6 maintenance cycles, or up to 1 year from first dose of BI-1206 (whichever occurs first).


Inclusion Criteria: - Are ≥ 18 years of age by initiation of study treatment. - Have B-cell NHL proven by histology, with histological subtypes limited to follicular lymphoma (FL) (except FL3B), MCL and marginal zone lymphoma (MZL). - Have measureable nodal disease - Are willing to undergo lymph node biopsies or biopsies of other involved tissue - Have relapsed disease or disease refractory to conventional treatment or for which no standard therapy exists. - Have received at least one line of conventional previous therapy which must include at least one rituximab-based regimen. - Have a life expectancy of at least 12 weeks - Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. - Have CD20+ malignancy - Have hematological and biochemical indices within prespecified ranges Exclusion Criteria: - Have had an allogenic bone marrow or stem cell transplant within 12 months - Have presence of active chronic graft versus host disease - Have current leptomeningeal lymphoma or compromise of the central nervous system. - Have transformed lymphoma from a pre-existing indolent lymphoma. - Have Waldenstrom's Macroglobulinemia or FL3B, - Need systemic doses of prednisolone >10 mg daily (or equipotent doses of other corticosteroids) while on the study trial other than as pre-medication. - Have known or suspected hypersensitivity to rituximab or BI-1206. - Have cardiac or renal amyloid light-chain amyloidosis. - Have received the following: - Chemotherapy or small molecule products with 2 weeks of first dose of BI-1206 - Radiotherapy (except for focal symptomatic control of lymphadenopathy) within 4 weeks - Immunotherapy within 8 weeks - Have ongoing toxic manifestations of previous treatments. - Have the ability to become pregnant (or already pregnant or lactating/breastfeeding). - Have had major surgery from which the subject has not yet recovered. - Are at high medical risk because of non-malignant systemic disease including active infection on treatment with antibiotics, antifungals or antivirals. - Are serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV). - Have an active, known or suspected autoimmune disease. - Have concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA]), - Have current malignancies of other types



Primary Contact:

Principal Investigator
Mats Jerkeman, MD PhD
Senior Consultant and Adjunct Professor, Skane Univ Hospital, Lund, Sweden

Susanne Gertsson
Phone: +46709102267

Backup Contact:

Andres McAllister, MD, PhD

Location Contact:

Atlanta, Georgia 30322
United States

Jonathon Cohen, MD

Site Status: Recruiting

Data Source:

Date Processed: June 21, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.